Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543229 | 1.00 | GRM8 (0.41) | GRM8GRM4GRM7ARG1GRIK1 | |
| SCHEMBL24295639 | 0.91 | NOS1 (0.45) | GRM8GRM4GRM7ARG1GRIK1 | |
| SCHEMBL15360000 | 0.83 | CYP1A2 (0.49) | GRIA1GRIA2GRIA3GRIA4HSD17B10 | |
| SCHEMBL25179498 | 0.79 | KMT2A (0.49) | GRM8GRM4GRIK1GRIK2KIF11 | |
| SCHEMBL31369923 | 0.79 | FFAR1 (0.43) | GRM4GRIK1GRIK2NOS1 | |
| SCHEMBL25179497 | 0.79 | KMT2A (0.49) | GRM8GRM4GRIK1GRIK2KIF11 | |
| SCHEMBL7996551 | 0.76 | FFAR1 (0.55) | ALDH1A1 | |
| SCHEMBL1768948 | 0.75 | SLC1A5 (0.56) | KIF11ALDH1A1 | |
| SCHEMBL1176394 | 0.75 | SLC1A5 (0.56) | KIF11ALDH1A1 | |
| SCHEMBL30428132 | 0.75 | SLC1A5 (0.56) | KIF11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6680329-B2 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | SANOFI-SYNTHELABO (FR) | 2004-01-20 | — | — | US | disclosed |
| US-20030207920-A1 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | SANOFI-AVENTIS (FR) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207920-A1 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | PROC, VKORC1, SERPINC1 | GRM8 4465/4885GRM4 4253/4885GRM7 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.